CN101217949B - 治疗睡眠-清醒病症 - Google Patents

治疗睡眠-清醒病症 Download PDF

Info

Publication number
CN101217949B
CN101217949B CN2006800253545A CN200680025354A CN101217949B CN 101217949 B CN101217949 B CN 101217949B CN 2006800253545 A CN2006800253545 A CN 2006800253545A CN 200680025354 A CN200680025354 A CN 200680025354A CN 101217949 B CN101217949 B CN 101217949B
Authority
CN
China
Prior art keywords
formula
sleep
enantiomer
eds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800253545A
Other languages
English (en)
Chinese (zh)
Other versions
CN101217949A (zh
Inventor
A·阿纳奥
W·H·I·M·德林肯博格
J·帕伦博
J·斯波恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK CORP
SK Biopharmaceuticals Co Ltd
Original Assignee
SK CORP
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101217949(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK CORP, SK Biopharmaceuticals Co Ltd filed Critical SK CORP
Publication of CN101217949A publication Critical patent/CN101217949A/zh
Application granted granted Critical
Publication of CN101217949B publication Critical patent/CN101217949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800253545A 2005-06-08 2006-06-07 治疗睡眠-清醒病症 Active CN101217949B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
US60/688,638 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
CN101217949A CN101217949A (zh) 2008-07-09
CN101217949B true CN101217949B (zh) 2012-10-17

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800253545A Active CN101217949B (zh) 2005-06-08 2006-06-07 治疗睡眠-清醒病症

Country Status (16)

Country Link
US (8) US8440715B2 (enExample)
EP (1) EP1890684B1 (enExample)
JP (1) JP5024635B2 (enExample)
KR (1) KR101335941B1 (enExample)
CN (1) CN101217949B (enExample)
AU (1) AU2006254899B2 (enExample)
BR (1) BRPI0613697A2 (enExample)
CA (1) CA2611713C (enExample)
DK (1) DK1890684T3 (enExample)
ES (1) ES2435403T3 (enExample)
FR (1) FR20C1014I2 (enExample)
NL (1) NL301037I2 (enExample)
PL (1) PL1890684T3 (enExample)
RU (1) RU2417077C2 (enExample)
TW (2) TW201328689A (enExample)
WO (1) WO2006133393A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
CA2612672C (en) * 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
KR102173587B1 (ko) * 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) * 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2014164969A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
WO2015010014A1 (en) * 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
WO2016061488A1 (en) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
SG11201901998WA (en) * 2016-09-06 2019-04-29 Jazz Pharmaceuticals International Iii Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP3523275B1 (en) * 2016-10-06 2023-09-27 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds for medical use
WO2018222954A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals International Iii Limited Methods and compositions for treating excessive sleepiness
EP3661911A4 (en) * 2017-07-31 2021-04-14 Jazz Pharmaceuticals Ireland Limited CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2023375326A1 (en) * 2022-11-07 2025-05-22 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173863A (zh) * 1995-02-11 1998-02-18 株式会社油公 邻氨基甲酰基－(d)－苯基丙氨醇化合物及其制备方法
CN1204316A (zh) * 1996-10-10 1999-01-06 Sk株式会社 O－氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
BR0207830A (pt) 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade
ES2291454T3 (es) 2001-02-27 2008-03-01 Ortho-Mcneil Pharmaceutical, Inc. Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
RU2300372C2 (ru) 2001-02-27 2007-06-10 Орто-Макнейл Фармасьютикал, Инк. Карбаматы для применения для предотвращения или лечения биполярного расстройства
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN101132787A (zh) 2004-10-28 2008-02-27 Sk株式会社 抑郁的辅助疗法
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
CN101272776B (zh) 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
WO2014164969A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173863A (zh) * 1995-02-11 1998-02-18 株式会社油公 邻氨基甲酰基－(d)－苯基丙氨醇化合物及其制备方法
CN1204316A (zh) * 1996-10-10 1999-01-06 Sk株式会社 O－氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法

Also Published As

Publication number Publication date
US8440715B2 (en) 2013-05-14
CN101217949A (zh) 2008-07-09
US20170158622A1 (en) 2017-06-08
AU2006254899A1 (en) 2006-12-14
RU2417077C2 (ru) 2011-04-27
US20090312416A1 (en) 2009-12-17
DK1890684T3 (da) 2013-10-14
RU2008100019A (ru) 2009-07-20
JP5024635B2 (ja) 2012-09-12
US20140350098A1 (en) 2014-11-27
BRPI0613697A2 (pt) 2011-01-25
TW201328689A (zh) 2013-07-16
US11753368B2 (en) 2023-09-12
KR101335941B1 (ko) 2013-12-04
US10351517B2 (en) 2019-07-16
FR20C1014I2 (fr) 2021-04-23
EP1890684A1 (en) 2008-02-27
PL1890684T3 (pl) 2014-05-30
CA2611713A1 (en) 2006-12-14
US20190367448A1 (en) 2019-12-05
US20250109099A1 (en) 2025-04-03
FR20C1014I1 (enExample) 2020-06-12
ES2435403T3 (es) 2013-12-19
NL301037I2 (nl) 2020-05-12
US20210078943A1 (en) 2021-03-18
US12209059B2 (en) 2025-01-28
US9604917B2 (en) 2017-03-28
TWI419681B (zh) 2013-12-21
US20130137764A1 (en) 2013-05-30
JP2008545795A (ja) 2008-12-18
WO2006133393A1 (en) 2006-12-14
EP1890684B1 (en) 2013-08-14
TW200716084A (en) 2007-05-01
CA2611713C (en) 2013-10-01
KR20080035565A (ko) 2008-04-23
US8877806B2 (en) 2014-11-04
US20240239740A1 (en) 2024-07-18
AU2006254899B2 (en) 2011-11-24
NL301037I1 (enExample) 2020-04-01

Similar Documents

Publication Publication Date Title
US12209059B2 (en) Treatment of sleep-wake disorders
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
KR101828934B1 (ko) 양극성 장애의 치료방법
KR101783633B1 (ko) 섬유근육통 증후군의 치료 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Seoul, South Kerean

Applicant after: SK Biopharmaceuticals Co., Ltd.

Address before: Seoul, South Kerean

Applicant before: SK Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SK LTD. TO: SK BIOPHARMACEUTICALS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant